MedTrace Logo

Treatment of Latent Tuberculosis in Socially Marginalised Citizens

NCT03266991 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-10-12

No results posted yet for this study

Summary

An open-label, randomised controlled trial comparing compliance to treatment for latent tuberculosis infection in socially marginalised citizens. Participants will be randomized to either daily isoniazid for 6 months or weekly rifapentine and isoniazid as directly observed therapy for twelve weeks.

Conditions

  • Compliance, Patient

Interventions

DRUG

Rifapentine

Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks

DRUG

Isoniazid

Treatment with daily isoniazid in 6 months

Sponsors & Collaborators

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Christian Wejse, MD PHD · Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-27
Primary Completion
2023-02-09
Completion
2023-02-09

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03266991 on ClinicalTrials.gov